Abstract

Alteplase (TPA) and tenecteplase is the thrombolytic agent used for treatment of acute ischemic stroke (AIS), alteplase approved by the USFDA. Recently, there has been interest in the thrombolytic tenecteplase, because it is more safe and effective. Objectives: The aim of the present study to compare the safety and efficacy of determine the intravenous alteplase and tenecteplase in acute ischemic stroke patients. Methods: This was a prospective observational study. A total of 102 patients of acute ischemic stroke confirmed by MRI/CT with in window period of 3 hours admitted during the study period were enrolled. 56 patients received alteplase and 46 patients received tenecteplase. Alteplase and tenecteplase agents were given to the patients 3 hours after the onset of symptom. Various parameters were assed in terms of socio-demographic data, NIHSS score, ICH and mortality. Results: Most of the patients were male in both the group. There is no significant difference in baseline NIHSS score among alteplase and tenecteplase group, whereas statistically significant difference on 24 hours and 7th day NIHSS score in both the group. Co morbidities like: Diabetes Mellitus, Hypertension and hyperlipidaemia was more in alteplase group. Intracerebral hemorrhage (ICH) and mortality was higher in alteplase group whereas functional outcome was better in tenecteplase group. Conclusion: Tenecteplase has better functional outcome, safety and efficacy as compared to alteplase for treatment of Acute Ischemic Stroke

Description